X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

RXDX

Closed

Prometheus Biosciences Inc

199.92
+0.18 (+0.09%)
Last Update: 16 Jun 2023 16:30:00
Yesterday: 199.74
Day's Range: 199.92 - 199.92
Send
When Written:
 
113.76
Prometheus Biosciences Inc is a biopharmaceutical company that develops and commercializes precision therapies and diagnostic tools for patients with inflammatory bowel disease (IBD). The company was founded in 2016 and is headquartered in San Diego, California.

Prometheus Biosciences' lead product candidate is PR600, a precision therapy for ulcerative colitis and Crohn's disease. The company also has a proprietary diagnostic platform, Prometheus360, which uses molecular and clinical data to personalize treatment for IBD patients.

In addition to its IBD focus, Prometheus Biosciences is also exploring precision therapies for other autoimmune diseases, including lupus and rheumatoid arthritis.

The company has partnerships with several pharmaceutical companies, including Takeda Pharmaceutical Company and Nestle Health Science. As of 2021, Prometheus Biosciences has raised over $400 million in funding from investors such as ARCH Venture Partners, GV, and Sequoia Capital.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.209
X